Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
2021 10 21
Journal Article
Authors:
Horwitz, M.E.;
Stiff, P.J.;
Cutler, C.;
Brunstein, C.;
Hanna, R.;
Maziarz, R.T.;
Rezvani, A.R.;
Karris, N.A.;
McGuirk, J.;
Valcarcel, D.;
Schiller, G.J.;
Lindemans, C.A.;
Hwang, W.Y.K.;
Koh, L.Piu;
Keating, A.;
Khaled, Y.;
Hamerschlak, N.;
Frankfurt, O.;
Peled, T.;
Segalovich, I.;
Blackwell, B.;
Wease, S.;
Freedman, L.S.;
Galamidi-Cohen, E.;
Sanz, G.
Secondary:
Blood
Volume:
138
Pagination:
1429-1440
Issue:
16
PMID:
34157093
URL:
https://pubmed.ncbi.nlm.nih.gov/34157093/
Keywords:
Adolescent; Adult; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Gamida Cell LTD; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Young Adult
Abstract:
Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid and lymphoid cell product derived from a single umbilical cord blood unit. We report results of a phase 3 trial to evaluate the efficacy of omidubicel compared with standard umbilical cord blood transplantation (UCBT). Between January 2017 and January 2020, 125 patients age 13 to 65 years with hematologic malignancies were randomly assigned to omidubicel vs standard UCBT. Patients received myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease (GVHD). The primary end point was time to neutrophil engraftment. The treatment arms were well balanced and racially diverse. Median time to neutrophil engraftment was 12 days (95% confidence interval [CI], 10-14 days) for the omidubicel arm and 22 days (95% CI, 19-25 days) for the control arm (P < .001). The cumulative incidence of neutrophil engraftment was 96% for patients receiving omidubicel and 89% for patients receiving control transplants. The omidubicel arm had faster platelet recovery (55% vs 35% recovery by 42 days; P = .028), had a lower incidence of first grade 2 to 3 bacterial or invasive fungal infection (37% vs 57%; P = .027), and spent more time out of hospital during the first 100 days after transplant (median, 61 vs 48 days; P = .005) than controls. Differences in GVHD and survival between the 2 arms were not statistically significant. Transplantation with omidubicel results in faster hematopoietic recovery and reduces early transplant-related complications compared with standard UCBT. The results suggest that omidubicel may be considered as a new standard of care for adult patients eligible for UCBT. The trial was registered at www.clinicaltrials.gov as #NCT02730299.
